​
​

BioNTech SE (BNTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

BioNTech SE Revenue Highlights

Latest Revenue (Y)

$3.82B

Latest Revenue (Q)

$187.60M

Main Segment (Y)

Commercial

Main Geography (Y)

UNITED STATES

BioNTech SE Revenue by Period

BioNTech SE Revenue by Year

DateRevenueChange
2023-12-31$3.82B-77.94%
2022-12-31$17.31B-8.78%
2021-12-31$18.98B3834.42%
2020-12-31$482.32M344.17%
2019-12-31$108.59M-14.88%
2018-12-31$127.58M107.11%
2017-12-31$61.60M-

BioNTech SE generated $3.82B in revenue during NA 2023, up -77.94% compared to the previous quarter, and up 2993.53% compared to the same period a year ago.

BioNTech SE Revenue by Quarter

DateRevenueChange
2024-03-31$187.60M-87.32%
2023-12-31$1.48B65.20%
2023-09-30$895.30M433.87%
2023-06-30$167.70M-86.87%
2023-03-31$1.28B-70.15%
2022-12-31$4.28B23.61%
2022-09-30$3.46B8.28%
2022-06-30$3.20B-49.86%
2022-03-31$6.37B15.22%
2021-12-31$5.53B-9.11%
2021-09-30$6.09B14.67%
2021-06-30$5.31B159.15%
2021-03-31$2.05B492.98%
2020-12-31$345.44M412.08%
2020-09-30$67.46M61.53%
2020-06-30$41.76M50.97%
2020-03-31$27.66M-1.16%
2019-12-31$27.99M-2.35%
2019-09-30$28.66M11.16%
2019-06-30$25.79M-1.41%
2019-03-31$26.15M-58.99%
2018-12-31$63.78M212.69%
2018-09-30$20.40M-

BioNTech SE generated $187.60M in revenue during Q1 2024, up -87.32% compared to the previous quarter, and up 4.38% compared to the same period a year ago.

BioNTech SE Revenue Breakdown

BioNTech SE Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Research And Development$3.50M$116.00M$102.70M$178.85M-
Commercial$3.82B$17.19B$18.87B$303.48M-
Other Sales Transactions---$33.00M-
Collaboration Agreement----$4.23M
Collaboration And License Agreement----$84.43M
Bill And Hold Transaction----$1.06M

BioNTech SE's latest annual revenue breakdown by segment (product or service), as of Dec 23: Commercial (99.91%), and Research And Development (0.09%).

BioNTech SE Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20
UNITED STATES$3.01B$12.71B$14.64B-
GERMANY$482.70M$2.24B$20.60M-
DELAWARE-$3.03B--

BioNTech SE's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (86.18%), and GERMANY (13.82%).

BioNTech SE Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BNTXBioNTech SE$3.82B$187.60M
SRPTSarepta Therapeutics$1.24B$362.93M
NVAXNovavax$983.71M$415.48M
PTCTPTC Therapeutics$937.82M$135.42M
CRSPCRISPR Therapeutics$370.00M$602.00K
DNAGinkgo Bioworks$251.46M$89.05M
KRYSKrystal Biotech$50.70M$83.84M
IOVAIovance Biotherapeutics$1.19M$58.55M
CWBRCohBar--
AVROAVROBIO--
ELEVElevation Oncology--
MDGLMadrigal Pharmaceuticals-$62.17M
OCEAOcean Biomedical--
HEPAHepion Pharmaceuticals--
ENVBEnveric Biosciences--

BNTX Revenue FAQ

What is BioNTech SE’s yearly revenue?

BioNTech SE's yearly revenue for 2023 was $3.82B, representing a decrease of -77.94% compared to 2022. The company's yearly revenue for 2022 was $17.31B, representing a decrease of -8.78% compared to 2021. BNTX's yearly revenue for 2021 was $18.98B, representing an increase of 3834.42% compared to 2020.

What is BioNTech SE’s quarterly revenue?

BioNTech SE's quarterly revenue for Q1 2024 was $187.6M, a -87.32% decrease from the previous quarter (Q4 2023), and a -85.31% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.48B, a 65.20% increase from the previous quarter (Q3 2023), and a -65.43% decrease year-over-year (Q4 2022). BNTX's quarterly revenue for Q3 2023 was $895.3M, a 433.87% increase from the previous quarter (Q2 2023), and a -74.13% decrease year-over-year (Q3 2022).

What is BioNTech SE’s revenue growth rate?

BioNTech SE's revenue growth rate for the last 3 years (2021-2023) was -79.88%, and for the last 5 years (2019-2023) was 3416.93%.

What are BioNTech SE’s revenue streams?

BioNTech SE's revenue streams in c 23 are Research And Development, and Commercial. Research And Development generated $3.5M in revenue, accounting 0.09% of the company's total revenue, down -96.98% year-over-year. Commercial generated $3.82B in revenue, accounting 99.91% of the company's total revenue, down -77.81% year-over-year.

What is BioNTech SE’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of BioNTech SE was Commercial. This segment made a revenue of $3.82B, representing 99.91% of the company's total revenue.